lonafarnib has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Trials ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | Recent Studies (post-2010) ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 1,459 | 368 | 396 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baulch-Brown, C; Ma, D; Molloy, TJ; Spencer, A; Yeh, SL | 1 |
1 other study(ies) available for lonafarnib and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Multiple Myeloma; Piperidines; Pyridines; Structure-Activity Relationship; Zoledronic Acid | 2007 |